These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35426113)

  • 1. Janus Kinase Inhibitors: Next-Generation Treatment for Uveitis.
    El-Shabrawi Y; Rath T; Heiligenhaus A
    Klin Monbl Augenheilkd; 2022 May; 239(5):695-701. PubMed ID: 35426113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of janus kinase inhibitors in the treatment of rheumatic diseases].
    Krüger K
    Internist (Berl); 2019 Nov; 60(11):1215-1220. PubMed ID: 31486859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
    El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
    Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
    Alten R; Mischkewitz M; Stefanski AL; Dörner T
    Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
    Nash P; Kerschbaumer A; Dörner T; Dougados M; Fleischmann RM; Geissler K; McInnes I; Pope JE; van der Heijde D; Stoffer-Marx M; Takeuchi T; Trauner M; Winthrop KL; de Wit M; Aletaha D; Baraliakos X; Boehncke WH; Emery P; Isaacs JD; Kremer J; Lee EB; Maksymowych WP; Voshaar M; Tam LS; Tanaka Y; van den Bosch F; Westhovens R; Xavier R; Smolen JS
    Ann Rheum Dis; 2021 Jan; 80(1):71-87. PubMed ID: 33158881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of Janus Kinase inhibitor selectivity.
    Choy EH
    Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis.
    Venetsanopoulou AI; Voulgari PV; Drosos AA
    Expert Rev Clin Immunol; 2022 May; 18(5):485-493. PubMed ID: 35535405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis.
    Alciati A; Di Carlo M; Siragusano C; Palumbo A; Masala IF; Atzeni F
    Expert Opin Biol Ther; 2022 Oct; 22(10):1311-1322. PubMed ID: 36168970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis.
    Nash P
    J Rheumatol; 2022 Jun; 49(6 Suppl 1):44-47. PubMed ID: 35293326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
    Kerrigan SA; McInnes IB
    Curr Rheumatol Rep; 2018 Nov; 20(12):83. PubMed ID: 30406861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
    Keeling S; Maksymowych WP
    Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
    Atzeni F; Popa CD; Nucera V; Nurmohamed MT
    Expert Rev Clin Immunol; 2022 Mar; 18(3):233-244. PubMed ID: 35129033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Levels of Omega-3 Fatty Acids and DHA Are Linked to Pain Reduction in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors.
    Chang CK; Chen PK; Chen CC; Chang SH; Chen CH; Chen DY
    Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors.
    Chan J; Gladman D
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):415-426. PubMed ID: 31171312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
    Miserocchi E; Giuffrè C; Cornalba M; Pontikaki I; Cimaz R
    Clin Rheumatol; 2020 Mar; 39(3):847-851. PubMed ID: 31897953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
    Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
    Arthritis Res Ther; 2022 Mar; 24(1):61. PubMed ID: 35232462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study.
    de Souza S; Williams R; Nikiphorou E
    BMC Rheumatol; 2024 Jan; 8(1):1. PubMed ID: 38229170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
    Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
    BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases.
    Singh JA
    BioDrugs; 2023 Sep; 37(5):625-635. PubMed ID: 37351790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.